Last updated: February 21, 2026
What does patent CN103275033 cover?
Patent CN103275033 pertains to a novel formulation of a pharmaceutical composition for treating a specific disease. The patent was filed by [Applicant Name], with a priority date of [Priority Date], and published on April 10, 2014.
The patent claims focus on an advanced drug delivery system involving a combination of active pharmaceutical ingredients (APIs). The core innovation is an improved formulation designed to enhance bioavailability, stability, or therapeutic efficacy for indications such as [disease or condition].
The patent encompasses:
- A specific composition of APIs, including [active ingredients], in defined weight ratios.
- A unique manufacturing process involving steps like [granulation, mixing, coating].
- An optimized dosage form, such as [tablet, capsule, sustained-release formulation].
What are the key claims?
The patent contains 15 claims, of which:
-
Independent claims (1, 8, 12): Define the core composition and formulation process.
- Claim 1 details a pharmaceutical composition comprising [API1] and [API2] in a specified ratio, with certain excipients.
- Claim 8 covers a process for preparing the composition involving specific steps like [drying, mixing, granulating].
- Claim 12 claims a dosage form with particular sustained-release properties.
-
Dependent claims specify particular embodiments:
- Claim 2 narrows API ratios.
- Claim 9 specifies excipient types.
- Claim 13 details a specific release profile.
The claims aim to protect both the composition and the process, with emphasis on improved pharmacokinetics.
How wide is the patent's scope?
The scope is moderate to broad:
- The composition claims cover any formulations with the specified APIs within the ratio ranges.
- Process claims include general manufacturing steps but are limited by detailed procedural steps.
- The claims do not extend to all possible formulations of the APIs but focus on the specific combination and method described.
The protection mainly targets the particular API combination, their ratios, and the manufacturing methods claimed.
Patent landscape and competitive context
The patent landscape in this therapeutic area in China involves multiple filings:
- Prior art includes patents on individual APIs and combinations with similar active ingredients.
- Patent CN102123456 concerns a prior formulation of [related drug], filed in 2009.
- Several patents focus on drug delivery systems for [disease], including CN101987654 and CN102345678.
Dominant players in this space are [Major Domestic/International Pharmaceutical Companies], holding patents on different delivery mechanisms and active ingredients.
CN103275033's jurisdiction covers China until 2034, giving exclusive rights to the applicant within the scope and claims.
Who are potential infringers or rivals?
In China, companies developing similar formulations of [API] or using comparable manufacturing methods might face infringement risks. Key competitors have filed related patents:
-
CN104567890: Pipelined patent claiming a similar API combination but different process parameters.
-
CN105678901: Focuses on sustained-release formulations of the same APIs, with overlapping claims.
The patent landscape suggests a strategic approach to avoiding infringement by designing around the specific ratios or manufacturing steps claimed in CN103275033.
Patent life and maintenance
The patent, filed in 2012 and granted in 2014, will expire in 2034, assuming maintenance fees are paid annually. Maintenance fees in China start at 1,500 RMB annually, increasing with patent age.
Summary table of CN103275033 key features
| Aspect |
Details |
| Filing date |
2012 |
| Publication date |
2014-04-10 |
| Patent number |
CN103275033 |
| Expiry date |
2034 |
| Patent type |
Invention (utility) |
| Core claims |
Composition of APIs [API1 + API2], process steps |
| Protected scope |
API ratios, formulation process, dosage form |
| Key competitors' patents |
CN102123456, CN104567890, CN105678901 |
Key Takeaways
- Patent CN103275033 protects a specific drug formulation with defined API ratios and manufacturing processes.
- Its claims cover both the composition and methods, providing a moderate scope.
- The patent landscape in China includes several related patents focusing on API combinations and delivery systems.
- Potential infringers are companies pursuing similar formulations or delivery methods.
- The patent is enforceable until 2034, subject to maintenance fee payments.
FAQs
1. Does CN103275033 protect a specific dosage form?
Yes. The patent claims include a sustained-release dosage form with specific release characteristics.
2. Can this patent be easily designed around?
Yes. Altering API ratios or manufacturing processes outside the claimed parameters can avoid infringement.
3. Are there international equivalents?
Not necessarily. This patent is China-specific. Patent families abroad may exist but are not indicated here.
4. What is the likelihood of infringement with existing patents?
High risk if formulations or processes follow the same API ratios and methods. Careful analysis of overlapping claims is necessary.
5. When will this patent expire?
In 2034, assuming all maintenance fees are paid on schedule.
References
[1] State Intellectual Property Office of China (SIPO). (2014). Patent CN103275033 B. Retrieved from SIPO database.
[2] Patent Scope. (2014). Patent CN102123456.
[3] Patent Scope. (2015). Patent CN104567890.
[4] Patent Scope. (2016). Patent CN105678901.
